Fulgent Genetics (FLGT) Share-based Compensation (2016 - 2026)

Fulgent Genetics has disclosed Share-based Compensation across 11 years of filings, most recently posting $9.9 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $9.9 million, down 6.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.9 million (down 10.55% YoY), and the FY2025 annual result was $39.6 million, down 11.01% from the prior year.
• Share-based Compensation came in at $9.9 million for Q1 2026 at Fulgent Genetics, up from $9.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $11.6 million in Q2 2024 to a low of $5.6 million in Q1 2022.
• The 5-year median for Share-based Compensation is $10.3 million (2023), against an average of $10.0 million.
• Across the five-year window, Share-based Compensation soared 127.74% in 2022 and declined 13.72% in 2025, its largest moves.
• Fulgent Genetics' Share-based Compensation stood at $10.0 million in 2022, then rose by 14.07% to $11.4 million in 2023, then decreased by 8.96% to $10.4 million in 2024, then decreased by 10.88% to $9.3 million in 2025, then rose by 6.62% to $9.9 million in 2026.
• The last three Share-based Compensation figures came in at $9.9 million (Q1 2026), $9.3 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.